Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 319

1.

Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial.

Hull RD, Schellong SM, Tapson VF, Monreal M, Samama MM, Nicol P, Vicaut E, Turpie AG, Yusen RD; EXCLAIM (Extended Prophylaxis for Venous ThromboEmbolism in Acutely Ill Medical Patients With Prolonged Immobilization) study.

Ann Intern Med. 2010 Jul 6;153(1):8-18. doi: 10.7326/0003-4819-153-1-201007060-00004.

PMID:
20621900
2.

Impact of age on the efficacy and safety of extended-duration thromboprophylaxis in medical patients. Subgroup analysis from the EXCLAIM randomised trial.

Yusen RD, Hull RD, Schellong SM, Tapson VF, Monreal M, Samama MM, Chen M, Deslandes B, Turpie AG.

Thromb Haemost. 2013 Dec;110(6):1152-63. doi: 10.1160/TH13-02-0170. Epub 2013 Oct 2.

PMID:
24085227
3.

Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.

Goldhaber SZ, Leizorovicz A, Kakkar AK, Haas SK, Merli G, Knabb RM, Weitz JI; ADOPT Trial Investigators.

N Engl J Med. 2011 Dec 8;365(23):2167-77. doi: 10.1056/NEJMoa1110899. Epub 2011 Nov 13.

4.

Extended-duration thromboprophylaxis in acutely ill medical patients with recent reduced mobility: methodology for the EXCLAIM study.

Hull RD, Schellong SM, Tapson VF, Monreal M, Samama MM, Turpie AG, Wildgoose P, Yusen RD.

J Thromb Thrombolysis. 2006 Aug;22(1):31-8.

PMID:
16786230
5.

Rivaroxaban for thromboprophylaxis in acutely ill medical patients.

Cohen AT, Spiro TE, Büller HR, Haskell L, Hu D, Hull R, Mebazaa A, Merli G, Schellong S, Spyropoulos AC, Tapson V; MAGELLAN Investigators.

N Engl J Med. 2013 Feb 7;368(6):513-23. doi: 10.1056/NEJMoa1111096.

6.

The design and rationale for the Acute Medically Ill Venous Thromboembolism Prevention with Extended Duration Betrixaban (APEX) study.

Cohen AT, Harrington R, Goldhaber SZ, Hull R, Gibson CM, Hernandez AF, Kitt MM, Lorenz TJ.

Am Heart J. 2014 Mar;167(3):335-41. doi: 10.1016/j.ahj.2013.11.006. Epub 2013 Dec 10.

7.

Standard or extended-duration prophylaxis in medical patients? A review of the evidence.

Stark JE, Smith WJ.

J Thromb Thrombolysis. 2011 Oct;32(3):318-27. doi: 10.1007/s11239-011-0594-5. Review.

PMID:
21553280
8.

Predicting the risk of venous thromboembolism in patients hospitalized with heart failure.

Mebazaa A, Spiro TE, Büller HR, Haskell L, Hu D, Hull R, Merli G, Schellong SW, Spyropoulos AC, Tapson VF, De Sanctis Y, Cohen AT.

Circulation. 2014 Jul 29;130(5):410-8. doi: 10.1161/CIRCULATIONAHA.113.003126. Epub 2014 Jun 26.

9.

Low-molecular-weight heparin and mortality in acutely ill medical patients.

Kakkar AK, Cimminiello C, Goldhaber SZ, Parakh R, Wang C, Bergmann JF; LIFENOX Investigators.

N Engl J Med. 2011 Dec 29;365(26):2463-72. doi: 10.1056/NEJMoa1111288.

10.

Venous thromboembolism risk in ischemic stroke patients receiving extended-duration enoxaparin prophylaxis: results from the EXCLAIM study.

Turpie AG, Hull RD, Schellong SM, Tapson VF, Monreal M, Samama MM, Chen M, Yusen RD; EXCLAIM Investigators.

Stroke. 2013 Jan;44(1):249-51. doi: 10.1161/STROKEAHA.112.659797. Epub 2012 Nov 1.

11.

Does ambulation modify venous thromboembolism risk in acutely ill medical patients?

Amin AN, Girard F, Samama MM.

Thromb Haemost. 2010 Nov;104(5):955-61. doi: 10.1160/TH10-04-0236. Epub 2010 Sep 13.

PMID:
20838741
12.

Summaries for patients. Do the benefits of prolonged low-molecular-weight heparin treatment outweigh the harms in hospitalized patients who are bedbound?

[No authors listed]

Ann Intern Med. 2010 Jul 6;153(1):I-50. doi: 10.7326/0003-4819-153-1-201007060-00002. No abstract available.

PMID:
20621897
13.

Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol.

Cohen AT, Spiro TE, Büller HR, Haskell L, Hu D, Hull R, Mebazaa A, Merli G, Schellong S, Spyropoulos A, Tapson V.

J Thromb Thrombolysis. 2011 May;31(4):407-16. doi: 10.1007/s11239-011-0549-x.

14.
15.

Extended-duration thromboprophylaxis with enoxaparin after arthroscopic surgery of the anterior cruciate ligament: a prospective, randomized, placebo-controlled study.

Marlovits S, Striessnig G, Schuster R, Stocker R, Luxl M, Trattnig S, Vécsei V.

Arthroscopy. 2007 Jul;23(7):696-702.

PMID:
17637403
16.

Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial.

Eriksson BI, Dahl OE, Huo MH, Kurth AA, Hantel S, Hermansson K, Schnee JM, Friedman RJ; RE-NOVATE II Study Group.

Thromb Haemost. 2011 Apr;105(4):721-9. doi: 10.1160/TH10-10-0679. Epub 2011 Jan 12.

PMID:
21225098
17.

D-dimer as a predictor of venous thromboembolism in acutely ill, hospitalized patients: a subanalysis of the randomized controlled MAGELLAN trial.

Cohen AT, Spiro TE, Spyropoulos AC, Desanctis YH, Homering M, Büller HR, Haskell L, Hu D, Hull R, Mebazaa A, Merli G, Schellong S, Tapson VF, Burton P; MAGELLAN Study Group.

J Thromb Haemost. 2014 Apr;12(4):479-87. doi: 10.1111/jth.12515.

18.

Extended thromboprophylaxis with low-molecular-weight heparins after hospital discharge in high-risk surgical and medical patients: a review.

Huo MH, Muntz J.

Clin Ther. 2009 Jun;31(6):1129-41. doi: 10.1016/j.clinthera.2009.06.002. Review.

PMID:
19695383
19.

Systematic review of randomized controlled trials of new anticoagulants for venous thromboembolism prophylaxis in major orthopedic surgeries, compared with enoxaparin.

Yoshida Rde A, Yoshida WB, Maffei FH, El Dib R, Nunes R, Rollo HA.

Ann Vasc Surg. 2013 Apr;27(3):355-69. doi: 10.1016/j.avsg.2012.06.010. Epub 2013 Jan 23. Review.

PMID:
23351997
20.

Enoxaparin: a review of its use as thromboprophylaxis in acutely ill, nonsurgical patients.

Siddiqui MA, Wagstaff AJ.

Drugs. 2005;65(7):1025-36. Review.

PMID:
15892594

Supplemental Content

Support Center